The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Company overview

Founded in 2006

Over 60 employees

Proprietary alfapump® & DSR technologies

Headquarters in Ghent, Belgium

Manufacturing in Zurich, Switzerland

Listed on Euronext Brussels

Media Library

In the news

Catch-up on our latest news coverage

Info sheet

Learn more about NASH, ascites, diuretic-resistant fluid overload and heart failure.


Watch and learn more about Sequana Medical, our alfapump® & DSR technologies and target disease areas.

Blog Post

Follow Sequana Medical’s blog posts.

Annual report

Discover more about our business activities in our latest annual report.

News, events and presentations

Read our latest news and discover upcoming & recent presentations.


Best Technology Award, European Mediscience Awards, June 2023

Best Overall Medical Device Product Award 4th Annual Medtech Breakthrough Awards, May 2020

Highly Commended Accolade within the Medtech of the Year Award 2019 Lifestars Awards, November 2019

Media Kit

Download our company logo and pictures.


For any kind of Media inquiry, please get in touch and our team will answer all of your questions.